Thirty Madison vs Ro

Side-by-side comparison of model-estimated upside.

Thirty Madison

—

est. 2Y upside i

Healthcare

Rank

#4294

Sector

HealthTech

Data Quality

—

Skipped: Exited (Acquisition by Remedy Meds)

Last updated: May 5, 2026

Ro

-38%

est. 2Y upside i

HealthcareSeries D+

Rank

#3135

Sector

Healthcare

Est. Liquidity

~3Y

Data Quality

Data: Low

Ro's equity carries significant downside risk over a 2-year horizon due to a stale $7B valuation and likely multiple compression toward public comps.

Last updated: July 21, 2026

Upside Comparison

Expected Upside

Thirty Madison
0%
Ro
-38%

Disclaimer: These rankings are AI-generated estimates and do not constitute financial or career advice. Always conduct your own due diligence.